FMT in Transplant-related Gastrointestinal Mucositis

NCT07622849 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Observational

Started

2023-03-01

Last updated

2026-06-03

Condition(s) studied

Transplant-related Gastrointestinal Mucositis

Investigational drug(s) / intervention(s)

Fecal Microbiota

Fecal Microbiota: fecal microbiota transplantation

Study summary

With the stem cell transplant increasing, patients which effected with transplant-related gastrointestinal mucositis (TRGM) have also increased. To evaluate the safety and efficacy of FMT for TRGM, patients with TRGM were recruited.

Eligibility

Sex

ALL

Min age

15 Years

Max age

65 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Transplant-related gastrointestinal mucositis Exclusion Criteria: * age\>65; or age\<15;

Primary outcome measure(s)

aGVHD — 2 weeks, 4 weeks, 2 months, 3 months
Occurrence time and severity of aGVHD

Trial sites (1)

Facility	City	Region	Status
Soochow University	Suzhou	Jiangsu

More The First Affiliated Hospital of Soochow University trials in China

A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML Recruiting

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Starting soon

A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia Starting soon

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07622849 on ClinicalTrials.gov ↗ ← All trials in China